Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: A single-institution experience

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1280-1285

  Gerl, A ^a   Clemm, C ^b   Schmeller, N ^a   Hartenstein, R ^c   Lamerz, R ^a   Wilmanns, W ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Clinic of Oncology Bad Trissl   (Germany)

^c City Hospital Munich Harlaching   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Chemotherapy; Etoposide; Non seminomatous germ cell tumour; Prognosis; Second neoplasm

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; GERM CELL TUMOR; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINUM MASS; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0029825266     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.530     Document Type: Article

References (33)

1. AASS N, KLEPP O, CAVALLIN-STAHL E, DAHL, O, WICKLUND H, UNSGAARD B, BALDETORP L, AHLSTRÖM S AND FOSSA SD. (1991). Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J. Clin. Oncol., 9, 818-826.
2. BAJORIN DF, MOTZER RJ, RODRIGUEZ E, MURPHY B AND BOSL GJ. (1993). Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J. Natl Cancer Inst., 85, 60-62.
3. BANIEL J, FOSTER RS, GONIN R. MESSEMER JE, DONOHUE JP AND EINHORN LH. (1995). Late relapse of testicular cancer. J. Clin. Oncol., 13, 1170-1176.
4. BOKEMEYER C, SCHMOLL H-J, KUCZYK MA, BEYER J AND SIEGERT W. (1995a). Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J. Natl Cancer Inst., 87, 58-60.
5. BOKEMEYER C, HARSTRICK A, RÜTHER U, METZNER B, ARSENIEV L, KADAR J, ILLIGER H-J, LINK H, RAICHLE A, BEYER J, HOSSFELD DK AND SCHMOLL HJ. (1995b). Sequential treatment with high-dose VIP-chemotherapy plus peripheral blood stem cell (PBSC) support in advanced germ cell cancer. Proc. Am. Soc. Clin. Oncol., 14, 230.
6. BOSHOFF C, BEGENT RHJ, OLIVER RTD, RUSTIN GJ, NEWLANDS ES, ANDREWS R, SKELTON M, HOLDEN I. AND ONG J. (1995). Secondary tumours following etoposide containing therapy for germ cell cancer. Ann. Oncol., 6, 35-40.
7. DEARNALEY DP, HORWICH A, A'HERN R. NICHOLLS J, JAY G, HENDRY WF AND PECKHAM MJ. (1991). Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metaslatic testicular teratoma: long-term follow-up. Eur. J. Cancer, 27, 684-691.
8. DIXON WJ. (1990). BMDP Statistical Software Manual. University of California Press: Berkeley, CA, USA.
9. EINHORN LH AND DONOHUE J. (1977). Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med., 87, 293-298.
10. EINHORN LH. (1986). Have new aggressive regimens improved results in advanced germ cell tumors? Eur. J. Cancer, 22, 1289-1293.
11. FEUER EJ, FREY CM, BRAWLEY OW, NAYFIELD SG, CUNNINGHAM JB, GELLER NL, BOSL GJ., KRAMER BS. (1994). After a treatment breakthrough: A comparison of trial and population-based data for advanced testicular cancer. J. Clin. Oncol., 12, 368-377.
12. FOSSA SD AND AASS N. (1989). Cisplatin-based chemotherapy does not eliminate the risk of a second testicular cancer. Br. J. Urol., 63, 531-534.
13. GERL A, CLEMM C, HENTRICH M, HARTENSTEIN R AND WILMANNS W. (1993). Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first-line chemotherapy for poorrisk non-seminomatous germ cell tumors. Acta Oncol., 32, 541-546.
14. GERL A. (1994). Vascular toxicity associated with chemotherapy for testicular cancer. Anti-cancer Drugs, 5, 607-614.
15. GERL A, CLEMM C, KOHL P, SCHALHORN A AND WILMANNS W. (1994a). Adjuvant chemotherapy of stage II nonseminomatous testicular cancer. Oncol. Rep., 1, 209-212.
16. GERL A, CLEMM C, SCHMELLER N, DIENEMANN H, WEISS M, KRIEGMAIR M, LÖHRS U AND WILMANNS W. (1994b). Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br. J. Cancer, 70, 960-965.
17. GERL A, CLEMM C, SCHMELLER N, DIENEMANN H, LAMERZ R, KRIEGMAIR M AND WILMANNS W. (1995a). Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann. Oncol., 6, 483-488.
18. GERL A, CLEMM C, SCHMELLER N, HARTENSTEIN R, LAMERZ R AND WILMANNS W. (1995b). Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br. J. Cancer, 72, 1026-1032.
19. HARDING MJ, PAUL J, GILLIS CR AND KAYE SB. (1993). Management of malignant teratoma: does referral to a specialist unit matter? Lancet, 341, 999-1002.
20. HATTON MQF, PAUL J, HARDING M, MACFARLANE G, ROBERTSON AG AND KAYE SB. (1995).Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours. Eur. J. Cancer, 31A, 1487-1491.
21. HITCHINS RN, NEWLANDS ES, SMITH DB, BEGENT RHJ, RUSTIN GJS AND BAGSHAWE KD (1989). Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br. J. Cancer, 59, 236-242.
22. HOELZEL D AND ALTWEIN JE. (1991). Hodentumoren: Ist der Rückgang der Mortalität in der Bundesrepublik Deutschland zu langsam erfolgt? Dtsch. Aerztebl., 88B, 2694-2700.
23. HORWICH A. (1989). Germ cell tumour chemotherapy. Br. J. Cancer, 59, 156-159.
24. HOWARD GCW, CLARKE K, ELIA MH, HUTCHEON AW, KAYE SB, WINDSOR PM, YOSEF HMA AND SHARP L (1995). A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. Br. J. Cancer, 72, 1307-1311.
25. KAPLAN EL AND MEIER P. (1958). Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
26. MANTEL N AND HAENSZEL W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst., 22, 719-748.
27. MEAD GM, STENNING SP, PARKINSON MC, HORWICH A, FOSSA SD, WILKINSON PM, KAYE SB, NEWLANDS ES AND COOK PA (1992). The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. J. Clin. Oncol., 10, 85-94.
28. NICHOLS CR, BREEDEN ES, LOEHRER PJ, WILLIAMS SD AND EINHORN LH. (1993). Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J. Natl Cancer Inst., 85, 36-40.
29. PEDERSEN-BJERGAARD J, DAUGAARD G, HANSEN SW, PHILIP P, LARSEN SO AND RORTH M. (1991). Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet, 338, 359-363.
30. PUGH RCB. (1976). Testicular tumours, introduction. In Pathology of the Testis, Pugh RCB (ed.), pp. 139-162. Blackwell Scientific Publications: Oxford.
31. STILLER CA, (1994). Centralised treatment, entry to trials and survival. Br. J. Cancer, 70, 352-362.
32. TIBSHIRANI R. (1982). A plain man's guide to the proportional hazards model. Clin. Invest. Med., 5, 63-68.
33. WILLIAMS SD, BIRCH R, EINHORN LH, IRWIN L, GRECO FA AND LOEHRER PJ. (1987). Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316, 1435-1440.